Factors associated with hospitalisation in children and young people with COVID-19 (N=606)
| Univariable OR (95% CIs) | Multivariable OR* (95% CIs) | |
| Female (vs male) | 1.2 (0.6 to 3.8) | 1.1 (0.6 to 2.4) |
| Age (years) | 1.0 (0.9 to 1.1) | 1.0 (0.9 to 1.0) |
| Rheumatic disease | ||
| JIA | (comparator) | (comparator) |
| SLE/MCTD, Vasculitis | 3.8 (1.8 to 8.1)† | 4.3 (1.7 to 11)† |
| Auto-inflammatory syndromes | 2.0 (0.8 to 4.9) | 3.0 (1.1 to 8.6)† |
| Other | 1.3 (0.4 to 4.1) | 1.7 (0.5 to 5.5) |
| Obesity | 3.1 (1.2 to 8.0)† | 4.0 (1.3 to 12)† |
| Glucocorticoid use | 2.7 (1.3 to 5.9)† | 2.1 (0.8 to 5.6) |
| DMARD use | ||
| None stated | (comparator) | (comparator) |
| csDMARD only | 0.9 (0.4 to 2.1) | 0.6 (0.2 to 1.7) |
| b/tsDMARD only | 0.9 (0.4 to 2.1) | 1.5 (0.6 to 3.6) |
| Combination therapy | 0.5 (0.2 to 1.3) | 0.4 (0.1 to 1.5) |
*Adjusted for disease activity (remission, low, moderate to high, or unknown) and dataset (EULAR COVID-19 Registry or CARRA (CARRA Registry and CARRA COVID-19 GPRD)).
†P<0.05.
b/tsDMARD, biologic or targeted-synthetic DMARD; CARRA, Childhood Arthritis and Rheumatology Research Alliance; csDMARD, conventional-synthetic DMARD; DMARD, disease modifying anti-rheumatic drug; EULAR, European Alliance of Associations for Rheumatology; GPRD, Global Paediatric Rheumatology Database; JIA, juvenile idiopathic arthritis; MCTD, mixed-connective tissue disease; SLE, systemic lupus erythematosus.